LEXINGTON, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial results for the third quarter ended September 30, 2023 and business updates. Recent Financial and Operational Highlights Achieved…Read More
T2 Biosystems Inc T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates
